Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

METHODS AND DEVICES FOR REPAIR OF SEVERED PERIPHERAL NERVES WITH ERYTHROPOIETIN

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • Publication Date:
    August 22, 2019
  • معلومة اضافية
    • Document Number:
      20190255220
    • Appl. No:
      16/280424
    • Application Filed:
      February 20, 2019
    • نبذة مختصرة :
      An implantable drug-delivery device for repairing a severed peripheral nerve. The drug-delivery device includes a matrix formed of a biopolymer and an erythropoietin (EPO) entrapped in the matrix. After in vivo implantation of the drug-delivery device, the EPO elutes over a period of 1 day to 12 weeks. Also disclosed is a method for repairing a severed peripheral nerve using the implantable drug-delivery device.
    • Claim:
      1. An implantable drug-delivery device for repairing a severed peripheral nerve, the drug-delivery device comprising a matrix formed of a biopolymer and an erythropoietin (EPO) entrapped in the matrix, wherein, after in vivo implantation of the drug-delivery device, the EPO elutes over 1 day to 12 weeks.
    • Claim:
      2. The implantable drug-delivery device of claim 1, wherein the matrix is a porous de-cellularized biopolymer matrix of a mammalian peripheral nerve.
    • Claim:
      3. The implantable drug-delivery device of claim 1, wherein the matrix is semipermeable and the biopolymer is chitosan, alginic acid, cellulose, elastin, fibrin, a glycosaminoglycan, gelatin, a collagen, or a mixture thereof.
    • Claim:
      4. The implantable drug-delivery device of claim 3, wherein the biopolymer is collagen type I, type II, or type III.
    • Claim:
      5. The implantable drug-delivery device of claim 4, wherein the biopolymer is type I collagen.
    • Claim:
      6. The implantable drug-delivery device of claim 5, wherein the EPO elutes over 1 to 7 days.
    • Claim:
      7. The implantable drug-delivery device of claim 5, wherein the EPO elutes over 1 to 3 weeks.
    • Claim:
      8. The implantable drug-delivery device of claim 5, wherein the EPO elutes over 3 to 6 weeks.
    • Claim:
      9. The implantable drug-delivery device of claim 5, wherein the EPO elutes over 6 to 12 weeks.
    • Claim:
      10. The implantable drug-delivery device of claim 1, wherein the device is in the form of a tube, a tubular wrapping cuff, a sheet, a rod, a strip, or a sponge.
    • Claim:
      11. A method for repairing a severed peripheral nerve having a proximal stump and a distal stump, the method comprising: providing an implantable drug-delivery device that includes a matrix formed of a biopolymer and an erythropoietin (EPO) entrapped in the matrix, inserting the proximal stump and the distal stump into a nerve guide implant and stabilizing the nerve stumps with a suture, and implanting the drug-delivery device at the site of the severed nerve, wherein, after implantation in vivo of the drug-delivery device, the EPO elutes over 1 day to 12 weeks.
    • Claim:
      12. The method of claim 11, wherein the matrix is a porous de-cellularized biopolymer matrix of a mammalian peripheral nerve and the implantable drug-delivery device is placed inside of the nerve guide implant prior to inserting the proximal stump and the distal stump.
    • Claim:
      13. The method of claim 11, wherein the matrix is semipermeable and the biopolymer is chitosan, alginic acid, cellulose, elastin, fibrin, a glycosaminoglycan, gelatin, a collagen, or a mixture thereof.
    • Claim:
      14. The method of claim 13, wherein the biopolymer is collagen type I, type II, or type III.
    • Claim:
      15. The method of claim 14, wherein the biopolymer is type I collagen.
    • Claim:
      16. The method of claim 15, wherein the EPO elutes over 1 to 7 days.
    • Claim:
      17. The method of claim 15, wherein the EPO elutes over 1 to 3 weeks.
    • Claim:
      18. The method of claim 15, wherein the EPO elutes over 3 to 6 weeks.
    • Claim:
      19. The method of claim 15, wherein the EPO elutes over 6 to 12 weeks.
    • Claim:
      20. The method of claim 11, wherein the device is in the form of a tube, a tubular wrapping cuff, a sheet, a rod, a strip, or a sponge.
    • Claim:
      21. The method of claim 20, wherein the drug-delivery device is affixed to an outer surface of the nerve guide implant.
    • Claim:
      22. The method of claim 20, wherein the drug-delivery device is affixed to an inner surface of the nerve guide implant prior to the attaching step.
    • Claim:
      23. The method of claim 11, wherein a gap between the proximal stump and the distal stump is 1 cm or less and the EPO elutes over 1 to 7 days.
    • Claim:
      24. The method of claim 11, wherein a gap between the proximal stump and the distal stump is 1 cm to 3 cm and the EPO elutes over 1 to 6 weeks.
    • Claim:
      25. The method of claim 11, wherein a gap between the proximal stump and the distal stump is 3 cm to 10 cm and the EPO elutes over 6 to 12 weeks.
    • Current International Class:
      61; 61; 61
    • الرقم المعرف:
      edspap.20190255220